FMNL1 and breast carcinoma: This further confirmed our conjecture because at first, in the systematic analysis of the expression and prognosis of FMNL1-3 in breast cancer, we found that FMNL1 was highly expressed in tumors but was associated with better prognosis, so it was not in line with the routine, which proved that FMNL1 acted as an immune cell marker.